

APPENDIX 3. INDICATORS USED IN EACH MODEL

TABLE 1. DRC-MALARIA

Group	Label in Diagram	Definition
Inputs	Lag of ITN Mass GF (\$)	Global Fund expenditure on ITN mass campaigns, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of ITN Cont. GF (\$)	Global Fund expenditure on ITN continuous distribution, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of ITN Other (\$)	Other donor disbursement on ITN distribution, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of Fac. Tx GF (\$)	Global Fund expenditure on facility-based case management of malaria, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of Case Mgmt Other (\$)	Other donor disbursement on facility-based case management of malaria, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of iCCM GF (\$)	Global Fund expenditure on integrated community case management, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of iCCM Other (\$)	Other donor disbursement on integrated community case management, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of GHE (\$)	Government health expenditure on malaria in general, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of Sev. Tx GF (\$)	Global Fund expenditure on facility-base case management of severe malaria, ("lag" meaning six months prior to activities indicators)
Inputs	Lag of IPTp GF (\$)	Global Fund expenditure on intermittent preventive treatment during pregnancy (IPTp), ("lag" meaning six months prior to activities indicators)
Activities	ITNs Rec. (#)	Number of insecticide-treated nets received (i.e. shipped from central to health zone level)

Activities	RDTs Rec. (#)	Number of rapid diagnostic tests received (i.e. shipped from central to health zone level)
Activities	ACTs Rec. (#)	Number of individual units of artemisinin combination therapy received (i.e. shipped from central to health zone level)
Outputs	ITNs Dist. (#)	Number of insecticide-treated nets distributed (i.e. given to people)
Outputs	RDTs Used (#)	Number of rapid diagnostic tests conducted
Outputs	Pat.'s Tx iCCM (#)	Number of patients with malaria treated in community care settings
Outputs	Pat.'s Tx (#)	Number of patients with uncomplicated malaria treated in facilities
Outputs	Sev. Tx (#)	Number of patients with severe malaria treated in facilities
Outputs	SP in ANC (#)	Number of patients treated with sulfadoxine-pyrimethamine (SP) in antenatal care (ANC) (any visit)
Outcomes	iCCM Tx. Cvg.	Proportion of suspected cases of malaria treated in community care settings
Outcomes	Tx Cvg. (mild)	Proportion of population-level cases of uncomplicated malaria treated with effective antimalarials
Outcomes	RDT Cvg.	Proportion of population-level cases of malaria tested with rapid diagnostic tests
Outcomes	Tx. Cvg. (severe)	Proportion of population-level cases of severe malaria treated with effective antimalarials
Outcomes	ITN Cvg.	Proportion of population who slept under insecticide-treated nets in the previous night
Outcomes	IPTp Cvg.	Proportion of antenatal care visits (1st visit) in which sulfadoxine-pyrimethamine was administered

TABLE 2. GUATEMALA-TB

Group	Label in Diagram	Definition
Inputs	GF TB Exp.	Global Fund expenditure on tuberculosis, excluding MDR-TB and TB/HIV modules, cumulatively summed since 2009.*
Inputs	GF MDR-TB Exp.	Global Fund expenditure on multidrug-resistant tuberculosis, cumulatively summed since 2009.*
Inputs	GF TB/HIV Exp.	Global Fund expenditure on HIV/TB, cumulatively summed since 2009.*
Inputs	GHE TB Exp.	Government health expenditure on tuberculosis, cumulatively summed since 2009.
Inputs	Other DAH TB Exp.	Development assistance from other donors for tuberculosis, cumulatively summed since 2009.
Activities	First-line drugs dist.	Drugs distributed which are first-line for the treatment of drug-susceptible TB (rifampicin, isoniazid, pyrazinamide, and ethambutol), cumulatively summed since 2009.
Activities	Second-line drugs dist.	TB drugs distributed which are not in the first-line category above. This category includes drugs used for treatment of MDR-TB, cumulatively summed since 2009.
Activities	Cases detected via ACF	Cases detected via active case finding by outreach workers, cumulatively summed since 2009 (activities did not start until 2017 for this variable)
Activities	GeneXpert testing for MDR	Number of tuberculosis patients tested with Xpert MTB/RIF, cumulatively summed since 2009.

Activities	TB patients tested for HIV	Number of tuberculosis patients tested for HIV, cumulatively summed since 2009.
Outputs	Cases Started Tx.	Persons with tuberculosis started on treatment, not counting MDR-TB or HIV/TB, cumulatively summed since 2009.
Outputs	Cases Notified	Number of persons with all-forms of TB notified to surveillance, cumulatively summed since 2009.
Outputs	Children <5 referred for TB screening	Children under 5 evaluated for TB screening through household contact investigation, cumulatively summed since 2009.
Outputs	MDR Cases Started Tx.	Persons with multidrug-resistant TB started on treatment, cumulatively summed since 2009.
Outputs	HIV/TB Cases Notified	Persons with HIV/TB co-infection notified to surveillance, cumulatively summed since 2009.
Outputs	Cases Notified in Prisons	Persons who reside in prisons and have TB notified, cumulatively summed since 2009.
Outcomes	Case notification rate	Persons notified with all-forms of TB per 100,000 population, quarterly since 2009.
Outcomes	Tx. success rate	Proportion of persons with drug-susceptible TB who complete treatment or have documentation of cure, quarterly since 2009.
Outcomes	Prop. HIV/TB cases treated	Proportion of HIV/TB cases notified who are started on treatment, quarterly since 2009.

Outcomes	HIV/TB tx. Success rate	Proportion of persons with HIV/TB co-infection who complete treatment or have documentation of cure, quarterly since 2009.
Outcomes	Prop. MDR-TB Cases Treated	Proportion of MDR-TB cases notified who are started on treatment, quarterly since 2009.
Outcomes	Children <5 started IPT	Children in contact with tuberculosis who started IPT, cumulatively summed since 2009.
Outcomes	Prop. Patients receiving DST	Proportion of persons with TB who were tested by WHO approved rapid diagnostic test (Xpert MTB/RIF), quarterly since 2009.
Outcomes	Prop. cases in prisons treated	Proportion of persons residing in prison who were found to have TB who were treated, quarterly since 2009.

TABLE 3. SENEGAL-TB

Group	Label in Diagram	Definition
Inputs	GF TB-HIV Exp	Global Fund spending on TB-HIV
Inputs	GF TB Comm Exp	Global Fund spending on TB Community Care
Inputs	GF Case D&D Exp	Global Fund spending on TB case detection and diagnosis
Inputs	Oth Case D&D Exp	Other development assistance for TB case detection and diagnosis
Inputs	GF MDR-TB Exp	Global Fund spending on TB-MDR

Inputs	Oth MDR-TB Exp	Other development assistance for TB-MDR
Activities	No. TB w/ HIV	TB patients diagnosed with HIV
Activities	No. social mobil	Number of social mobilizations
Activities	No. home visits	Number of home visits to identify presumed TB cases (people with cough longer than 2 weeks)
Activities	No. radio bcsts	Number of radio broadcasts
Activities	Lab prf rate	Laboratory performance rate (percentage deemed high quality)
Activities	No. GeneXpert tests	Number of patients tested with GeneXpert
Outputs	No. TB-HIV on ARV	TB/HIV patients on ARVs
Outputs	No. child ref	Number of child TB contacts referred to care
Outputs	No. ppl w/ cough ref	Number of people with cough longer than 2 weeks referred to care
Outputs	No. TB dx in oth ways	Cases identified through other means (Total cases identified minus cases identified by GeneXpert)
Outputs	No. TB dx by GeneXpert	Total cases diagnosed by GeneXpert
Outputs	No. MDR-TB cases dx	Number of MDR-TB cases
Outputs	No. Tx First-line	Total number of TB cases treated (first-line)
Outcomes	TB Tx Success Rate	TB treatment success rate
Outcomes	No. child on IPT	Chemoprevention for healthy children, ages 0-5

Outcomes	No. MDR-TB Cured	Number of cases of MDR-TB cured
----------	------------------	---------------------------------